



ASX ANNOUNCEMENT

29 August 2025

## FY2025 Preliminary Results Summary and Company Update

Cardiex Limited (ASX: CDX) (“**Cardiex**” or the “**Company**”) wishes to provide shareholders with a summary of its FY25 results and further clarity on the Company’s financial position and operational progress.

- **Revenue**

Revenue (ex-Clinichain) <sup>1</sup>	FY25 (m)	FY24 (m)
Sales	3.6	3.2
Other	2.7	2.2
<b>Total Revenue</b>	<b>6.3</b>	<b>5.4</b>

1. Excluding the \$7.7m Clinichain revenue recorded in FY24, Cardiex delivered a 10% increase in revenue in FY25, including first revenues from the Pulse, which launched in H2 FY25.

- **Expenses**

During H2 FY25, the Company implemented significant operational and streamlining initiatives that have significantly reduced the expense base to an annualised \$10 - \$12m (excluding COGS and marketing). This represents a substantial reduction compared to FY24 and early FY25 levels, positioning the Company with a leaner, more sustainable cost structure.

- **Cash**

Cash as of 30 June 2025 was \$2.4m, with a further \$1.2m due this quarter from the June placement (subject to the relevant shareholder approvals at the EGM on 17 September 2025) and c.\$1.6m from the FY25 R&D Incentive cash rebate in the coming months.

These inflows will further strengthen liquidity to support operations and growth initiatives.

- **Net Assets and Capital Position**

Net assets increased in the year by 37% to \$5.6m.

C2 Ventures (C2V) has confirmed its full participation in the June Placement (subject to shareholder approval at the upcoming EGM) and has advised of its intention to provide further capital support.

This endorsement from C2V, combined with cost reductions and new revenue streams from Pulse and Xcel, places Cardiex in a stronger financial position to execute on its FY26 growth strategy.



**Approved by the Executive Chairman and Released by the Company Secretary**

**- ENDS -**

For more information, please contact:

**Investor Relations**

Rod Hinchcliffe

[rod.hinchcliffe@mcpartners.com.au](mailto:rod.hinchcliffe@mcpartners.com.au)

**Media Relations**

Melissa Hamilton

[melissa.hamilton@mcpartners.com.au](mailto:melissa.hamilton@mcpartners.com.au)

**About CARDIEX**

Cardiex's mission is to increase longevity through medical technology advancements in vascular health. The Company's suite of products includes medical and home health devices and digital solutions for hypertension, cardiovascular disease, and other vascular health disorders - all based on the Company's market-leading SphygmoCor® vascular biomarker technology. Cardiex is listed on the Australian Stock Exchange ("ASX: CDX").